Intellia Therapeutics, Inc., a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs. Its ex vivo pipeline includes proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune diseases; and partnered programs focused on chimeric antigen receptor T cells and hematopoietic stem cells. Intellia Therapeutics, Inc. has collaboration agreement with Novartis Institutes for BioMedical Research, Inc.; Regeneron Pharmaceuticals, Inc.; and Caribou Biosciences, Inc. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Phone857-285-6200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$30.43 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/7/2019 (Estimated)
OptionableOptionable
Intellia Therapeutics (NASDAQ:NTLA) Frequently Asked Questions
What is Intellia Therapeutics' stock symbol?
Intellia Therapeutics trades on the NASDAQ under the ticker symbol "NTLA."
How were Intellia Therapeutics' earnings last quarter?
Intellia Therapeutics Inc (NASDAQ:NTLA) posted its quarterly earnings results on Wednesday, February, 27th. The company reported ($0.43) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.55) by $0.12. The firm had revenue of $7.90 million for the quarter, compared to analysts' expectations of $9.92 million. Intellia Therapeutics had a negative return on equity of 30.59% and a negative net margin of 280.42%. The company's revenue for the quarter was up 17.9% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.61) EPS. View Intellia Therapeutics' Earnings History.
When is Intellia Therapeutics' next earnings date?
What price target have analysts set for NTLA?
7 equities research analysts have issued twelve-month target prices for Intellia Therapeutics' shares. Their predictions range from $20.00 to $57.50. On average, they anticipate Intellia Therapeutics' share price to reach $28.90 in the next twelve months. This suggests a possible upside of 78.8% from the stock's current price. View Analyst Price Targets for Intellia Therapeutics.
What is the consensus analysts' recommendation for Intellia Therapeutics?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intellia Therapeutics in the last year. There are currently 4 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Intellia Therapeutics.
What are Wall Street analysts saying about Intellia Therapeutics stock?
Here are some recent quotes from research analysts about Intellia Therapeutics stock:
- 1. Chardan Capital analysts commented, "We see the current optimizations of the in vivo editing program as a step in that direction. Over the course of 2018, Intellia has also advanced its ex vivo engineered T cell receptor (TCR) cell therapy program and plans to nominate an autologous WT1-targeted TCR candidate for acute myeloid leukemia by the end of 2019." (2/27/2019)
- 2. According to Zacks Investment Research, "Intellia Therapeutics is a leading genome editing company, focused on developing therapeutics utilizing a biological tool known as CRISPR-Cas9 system. It believes the CRISPR-Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene. The guide RNA sequence recognizes and directs the Cas9 to a specific target deoxyribonucleic acid (DNA) sequence. The Company's sentinel in vivo programs focus on the use of Lipid Nanoparticle (LNPs) for delivery of the CRISPR/Cas9 complex to the liver. Intellia's combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts it in a unique position to unlock broad therapeutic applications of the CRISPR-Cas9 technology and create a new class of therapeutic products. " (1/29/2019)
Has Intellia Therapeutics been receiving favorable news coverage?
Press coverage about NTLA stock has been trending somewhat positive on Saturday, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Intellia Therapeutics earned a media sentiment score of 0.9 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 2.0 out of 10, indicating that recent press coverage is very unlikely to have an effect on the stock's share price in the immediate future.
Who are some of Intellia Therapeutics' key competitors?
Some companies that are related to Intellia Therapeutics include Quidel (QDEL), Myriad Genetics (MYGN), Lantheus (LNTH), Meridian Bioscience (VIVO), Quotient (QTNT), Oxford Immunotec Global (OXFD), Palatin Technologies (PTN), Nymox Pharmaceutical (NYMX), Vermillion (VRML), Trinity Biotech (TRIB), Celldex Therapeutics (CLDX), Riot Blockchain (RIOT), ImmuCell (ICCC), Achieve Life Sciences (ACHV) and GeneNews (GNWSF).
What other stocks do shareholders of Intellia Therapeutics own?
Who are Intellia Therapeutics' key executives?
Intellia Therapeutics' management team includes the folowing people:
- Dr. John M. Leonard, Pres, CEO & Director (Age 62)
- Mr. Nessan Bermingham Ph.D., Founder & Member of Scientific Advisor Board (Age 46)
- Mr. José E. Rivera, Exec. VP & Gen. Counsel (Age 53)
- Ms. Rachel Haurwitz Ph.D., Co-Founder (Age 33)
- Mr. Andrew May Ph.D., Founder and Member of Scientific Advisor Board
When did Intellia Therapeutics IPO?
(NTLA) raised $85 million in an initial public offering (IPO) on Friday, May 6th 2016. The company issued 5,000,000 shares at $16.00-$18.00 per share. Credit Suisse, Jefferies and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.
Who are Intellia Therapeutics' major shareholders?
Intellia Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.61%), FMR LLC (5.56%), Ontario Teachers Pension Plan Board (3.82%), Northern Trust Corp (0.90%), Orbimed Advisors LLC (0.87%) and Geode Capital Management LLC (0.83%). Company insiders that own Intellia Therapeutics stock include Andrew Schiermeier, Caribou Biosciences, Inc, Institutes For Biomed Novartis, Jean Francois Formela, John M Leonard, Nessan Bermingham and Venture Fund Ix LP Atlas. View Institutional Ownership Trends for Intellia Therapeutics.
Which major investors are selling Intellia Therapeutics stock?
NTLA stock was sold by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, First Trust Advisors LP, WS Management Lllp, FMR LLC, Great West Life Assurance Co. Can, K.J. Harrison & Partners Inc, Bank of America Corp DE and MetLife Investment Advisors LLC. Company insiders that have sold Intellia Therapeutics company stock in the last year include Jean Francois Formela and John M Leonard. View Insider Buying and Selling for Intellia Therapeutics.
Which major investors are buying Intellia Therapeutics stock?
NTLA stock was acquired by a variety of institutional investors in the last quarter, including Ontario Teachers Pension Plan Board, Dimensional Fund Advisors LP, Dimensional Fund Advisors LP, Two Sigma Investments LP, BlackRock Inc., Lord Abbett & CO. LLC, Tekla Capital Management LLC and Millennium Management LLC. View Insider Buying and Selling for Intellia Therapeutics.
How do I buy shares of Intellia Therapeutics?
Shares of NTLA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Intellia Therapeutics' stock price today?
One share of NTLA stock can currently be purchased for approximately $16.16.
How big of a company is Intellia Therapeutics?
Intellia Therapeutics has a market capitalization of $730.84 million and generates $30.43 million in revenue each year. The company earns $-85,340,000.00 in net income (profit) each year or ($1.98) on an earnings per share basis.
What is Intellia Therapeutics' official website?
How can I contact Intellia Therapeutics?
Intellia Therapeutics' mailing address is 40 ERIE STREET SUITE 130, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-285-6200 or via email at [email protected]
MarketBeat Community Rating for Intellia Therapeutics (NASDAQ NTLA)
MarketBeat's community ratings are surveys of what our community members think about Intellia Therapeutics and other stocks. Vote "Outperform" if you believe NTLA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NTLA will underperform the S&P 500 over the long term. You may vote once every thirty days.
